To read the full story, subscribe or sign in.

Santhera Licenses European Idebenone Rights To Takeda

Aug. 10, 2005

Santhera Pharmaceuticals AG licensed to Takeda the European rights to its Friedreich's Ataxia (FRDA) treatment, idebenone, in a deal which earned it an up-front payment of EUR5 million (US$6.2 million). (BioWorld International)

BioWorld Asia

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...